Equels Thomas K: insider trades.
Equels Thomas K reported 4 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 4 open-market purchases ($13K) and 0 sales, across 1 company.
- Transactions
- 4
- Purchases (P)
- 4
- Sales (S)
- 0
- Companies
- 1
- Name as filed
- Equels Thomas K
Companies
| Company | Relationship | Transactions |
|---|---|---|
| AIM ImmunoTech Inc. (AIM) | Director, Officer · CEO & President | 4 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-17 | AIM ImmunoTech Inc. | P | 24,000 | $0.21 | 126,822 | Form 4 |
| 2026-09-16 | AIM ImmunoTech Inc. | P | 11,000 | $0.21 | 102,822 | Form 4 |
| 2026-09-15 | AIM ImmunoTech Inc. | P | 22,000 | $0.22 | 91,822 | Form 4 |
| 2026-09-14 | AIM ImmunoTech Inc. | P | 5,900 | $0.22 | 69,822 | Form 4 |
Questions
What stock did Equels Thomas K buy or sell?
Equels Thomas K reported 4 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 4 open-market purchases ($13K) and 0 sales, across 1 company.
Is Equels Thomas K the same person as other filers with this name?
This page covers SEC CIK 1450324 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/equels-thomas-k-1450324.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.